• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Circulating Tumor DNA and Unique Actionable Genomic Alterations in the Longitudinal Monitoring of Metastatic Breast Cancer: A Case of Gene Fusion.

作者信息

Nicolò Eleonora, Munoz-Arcos Laura, Vagia Elena, D'Amico Paolo, Reduzzi Carolina, Donahue Jeannine, Lorico-Rappa Marco, Manai Maroua, Behdad Amir, Zhang Youbin, Curigliano Giuseppe, Shah Ami, Cristofanilli Massimo

机构信息

Division of New Drugs and Early Drug Development, European Institute of Oncology IRCCS, Milan, Italy.

Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.

出版信息

JCO Precis Oncol. 2023 Jul;7:e2200702. doi: 10.1200/PO.22.00702.

DOI:10.1200/PO.22.00702
PMID:37437229
Abstract
摘要

相似文献

1
Circulating Tumor DNA and Unique Actionable Genomic Alterations in the Longitudinal Monitoring of Metastatic Breast Cancer: A Case of Gene Fusion.循环肿瘤DNA与转移性乳腺癌纵向监测中的独特可操作基因组改变：一例基因融合病例
JCO Precis Oncol. 2023 Jul;7:e2200702. doi: 10.1200/PO.22.00702.
2
Genomic Profiling of Premenopausal HR+ and HER2- Metastatic Breast Cancer by Circulating Tumor DNA and Association of Genetic Alterations With Therapeutic Response to Endocrine Therapy and Ribociclib.采用循环肿瘤 DNA 对绝经前 HR+ 和 HER2- 转移性乳腺癌进行基因组分析，以及遗传改变与内分泌治疗和瑞博西利治疗反应的关系。
JCO Precis Oncol. 2021 Sep 1;5. doi: 10.1200/PO.20.00445. eCollection 2021.
3
Circulating Tumor DNA Analysis Detects Amplification and Concurrent Genomic Alterations Associated with FGFR Inhibitor Efficacy in Advanced Gastric Cancer.循环肿瘤 DNA 分析检测晚期胃癌中与 FGFR 抑制剂疗效相关的扩增和同时发生的基因组改变。
Clin Cancer Res. 2021 Oct 15;27(20):5619-5627. doi: 10.1158/1078-0432.CCR-21-1414. Epub 2021 Aug 10.
4
Comprehensive Genomic Profiling of Cell-Free Circulating Tumor DNA Detects Response to Ribociclib Plus Letrozole in a Patient with Metastatic Breast Cancer.基于游离循环肿瘤 DNA 的全面基因组分析检测到转移性乳腺癌患者使用来曲唑联合瑞博西利的应答。
Biomolecules. 2022 Dec 6;12(12):1818. doi: 10.3390/biom12121818.
5
-Altered Gastroesophageal Adenocarcinomas Are an Uncommon Clinicopathologic Entity with a Distinct Genomic Landscape.- 胃食管交界部腺癌的形态学改变是一种罕见的临床病理实体，具有独特的基因组特征。
Oncologist. 2019 Nov;24(11):1462-1468. doi: 10.1634/theoncologist.2019-0121. Epub 2019 Jun 27.
6
Circulating tumour DNA in metastatic breast cancer to guide clinical trial enrolment and precision oncology: A cohort study.循环肿瘤 DNA 用于指导转移性乳腺癌临床试验入组和精准肿瘤学：一项队列研究。
PLoS Med. 2020 Oct 1;17(10):e1003363. doi: 10.1371/journal.pmed.1003363. eCollection 2020 Oct.
7
Allele-specific regulation of FGFR2 expression is cell type-dependent and may increase breast cancer risk through a paracrine stimulus involving FGF10.FGFR2 表达的等位基因特异性调节依赖于细胞类型，并且可能通过涉及 FGF10 的旁分泌刺激增加乳腺癌风险。
Breast Cancer Res. 2011 Jul 18;13(4):R72. doi: 10.1186/bcr2917.
8
Next-Generation Sequencing of Tissue and Circulating Tumor DNA: The UC San Diego Moores Center for Personalized Cancer Therapy Experience with Breast Malignancies.组织和循环肿瘤 DNA 的下一代测序：加州大学圣地亚哥莫尔斯个性化癌症治疗中心在乳腺癌方面的经验。
Mol Cancer Ther. 2019 May;18(5):1001-1011. doi: 10.1158/1535-7163.MCT-17-1038. Epub 2019 Mar 29.
9
FGFR2-IIIb Expression by Immunohistochemistry Has High Specificity in Cholangiocarcinoma with FGFR2 Genomic Alterations.免疫组织化学检测 FGFR2-IIIb 表达在具有 FGFR2 基因组改变的胆管癌中具有高特异性。
Dig Dis Sci. 2022 Aug;67(8):3797-3805. doi: 10.1007/s10620-021-07303-9. Epub 2021 Nov 13.
10
[Association of FGFR2 gene polymorphism with estrogen receptor positive breast cancer detected by fluorescent quantitative PCR].荧光定量PCR检测FGFR2基因多态性与雌激素受体阳性乳腺癌的相关性
Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2010 Aug;27(4):445-8. doi: 10.3760/cma.j.issn.1003-9406.2010.04.019.

引用本文的文献

1
Understanding and Overcoming Resistance to Selective FGFR Inhibitors across FGFR2-Driven Malignancies.理解并克服 FGFR2 驱动的恶性肿瘤中对选择性 FGFR 抑制剂的耐药性。
Clin Cancer Res. 2024 Nov 1;30(21):4943-4956. doi: 10.1158/1078-0432.CCR-24-1834.